Back to results
US 10,206,988 B2Granted
Xenoantigen-displaying anti-cancer vaccines and method of making
AssigneeThe University of Toledo
InventorsSteven J. Sucheck, Katherine A. Wall, Sourav Sarkar
Life of this patent
Estimating the term…
Abstract
Compositions, methods of making, and methods of using, xenoantigen-displaying anti-cancer vaccines are described.
Claims12
A composition, comprising:
- an antigen composition consists essentially of one of compounds 9, 17, or 21:
- a xenoantigen composition comprising a second lipid moiety, a second linker moiety, and a xenoantigen moiety;
- and
- at least one liposomal formulation, wherein the antigen composition and the xenoantigen composition are embedded in the liposomal formulation;
- wherein:
- the xenoantigen moiety contains a structure comprising:
- an α- or β-linked L-rhamnose epitope, a β-linked α-Gal disaccharide epitope, or an α- or β-linked Forssman disaccharide epitope:
- and
- the second linker moiety comprises a chain of C1-m alkyl, dialkyl substituted aryl C1-m alkyl, or —CH2CH2(OCH2CH2)m—, wherein m is a positive integer.
6 more elements
A composition, comprising:
- an antigen composition comprising a first lipid moiety, a first linker moiety, and an antigen moiety;
- a xenoantigen composition comprising a second lipid moiety, a second linker moiety, and a xenoantigen moiety;
- and
- at least one liposomal formulation, wherein the antigen composition and the xenoantigen composition are embedded in the liposomal formulation;
- wherein:
- the antigen moiety comprises a Pam3Cys-MUC1 VNTR-TACA conjugate;
- the first lipid moiety comprises a Toll-like receptor (TLR) agonist ligand;
- the first linker moiety comprises a chain of C1-n alkyl, dialkyl substituted aryl C1-n alkyl, or —CH2CH2(OCH2CH2)n—, wherein n is a positive integer;
- and
- the xenoantigen moiety comprises α- or β-linked L-rhamnose.
7 more elements
A composition, comprising:
- an antigen composition comprising a first lipid moiety, a first linker moiety, and an antigen moiety;
- a xenoantigen composition comprising a second lipid moiety, a second linker moiety, and a xenoantigen moiety;
- and
- at least one liposomal formulation, wherein the antigen composition and the xenoantigen composition are embedded in the liposomal formulation;
- wherein the antigen composition consists essentially of compound 21:
2 more elements
A composition comprising:
- an antigen composition comprising a first lipid moiety, a first linker moiety, and an antigen moiety, wherein the antigen composition comprises a Pam3Cys-MUC1 VNTR-TACA conjugate;
- a xenoantigen composition comprising a second lipid moiety, a second linker moiety, and a xenoantigen moiety, wherein the second linker moiety comprises a tetraethyleneglycol (TEG) portion and the xenoantigen moiety comprises α- or β-linked L-rhamnose;
- and
- at least one liposomal formulation, wherein the antigen composition and the xenoantigen composition are embedded in the liposomal formulation.
1 more element
Dependencies are inferred from the claim text.